[go: up one dir, main page]

MX2020013284A - Vacuna basada en particulas virales. - Google Patents

Vacuna basada en particulas virales.

Info

Publication number
MX2020013284A
MX2020013284A MX2020013284A MX2020013284A MX2020013284A MX 2020013284 A MX2020013284 A MX 2020013284A MX 2020013284 A MX2020013284 A MX 2020013284A MX 2020013284 A MX2020013284 A MX 2020013284A MX 2020013284 A MX2020013284 A MX 2020013284A
Authority
MX
Mexico
Prior art keywords
viral particle
based vaccine
hcmv
strain
dense bodies
Prior art date
Application number
MX2020013284A
Other languages
English (en)
Inventor
Bodo Plachter
Inessa Penner
Original Assignee
Vakzine Projekt Man Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Man Gmbh filed Critical Vakzine Projekt Man Gmbh
Publication of MX2020013284A publication Critical patent/MX2020013284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de ácido nucleico que codifican para una cepa de citomegalovirus recombinante de humano (HCMV), a cuerpos densos producidos por dicha cepa de HCMV y preparaciones de dichos cuerpos densos para ser utilizadas en medicina, de manera particular como una vacuna contra HCMV.
MX2020013284A 2018-06-08 2019-06-07 Vacuna basada en particulas virales. MX2020013284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18176735 2018-06-08
PCT/EP2019/064941 WO2019234219A1 (en) 2018-06-08 2019-06-07 Viral particle - based vaccine

Publications (1)

Publication Number Publication Date
MX2020013284A true MX2020013284A (es) 2021-02-22

Family

ID=62567558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013284A MX2020013284A (es) 2018-06-08 2019-06-07 Vacuna basada en particulas virales.

Country Status (7)

Country Link
US (1) US11986521B2 (es)
EP (1) EP3801610A1 (es)
JP (1) JP7449246B2 (es)
AU (1) AU2019280899A1 (es)
CA (1) CA3094216A1 (es)
MX (1) MX2020013284A (es)
WO (1) WO2019234219A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US7204990B1 (en) * 2000-11-28 2007-04-17 Medimmune Vaccines, Inc. Attenuation of cytomegalovirus virulence
RU2505314C2 (ru) * 2007-05-11 2014-01-27 Вакцине Проджект Менеджмент Гмбх Композиция, содержащая частицы hcmv
DK2556150T3 (en) 2010-04-06 2016-12-05 Vakzine Projekt Man Gmbh A viral particle released after infection of mammalian cells by human cytomegalovirus (HCMV) containing a fusion protein and use thereof
MX363307B (es) * 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
EP2909228A1 (en) * 2012-10-19 2015-08-26 CEVEC Pharmaceuticals GmbH Production of a hcmv based vaccine in human amniocyte cell lines
US20150307850A1 (en) * 2012-12-04 2015-10-29 Merck Sharp & Dohme Corp. Conditional replicating viral vectors

Also Published As

Publication number Publication date
JP2021525535A (ja) 2021-09-27
AU2019280899A1 (en) 2020-10-08
EP3801610A1 (en) 2021-04-14
CA3094216A1 (en) 2019-12-12
US11986521B2 (en) 2024-05-21
WO2019234219A1 (en) 2019-12-12
JP7449246B2 (ja) 2024-03-13
US20210228711A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PH12018500855A1 (en) Herpes simplex virus vaccine
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
EP4242223A3 (en) Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
GB2513768A (en) Complexes of cytomegalovirus proteins
EP4349404A3 (en) Respiratory virus vaccines
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
PH12015501526B1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
PH12016502220A1 (en) Means and methods for treating cmv
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
MX2020001655A (es) Vacuna vph.
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX2016012840A (es) Moléculas para transporte de antígeno modular mejoradas y sus usos.
WO2016116905A9 (en) Cmv antigens and uses thereof
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
PH12014500369A1 (en) Influenza h5 vaccines
ZA202003070B (en) Lassa vaccine
MX2017009889A (es) Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.
MX2020013284A (es) Vacuna basada en particulas virales.
EP4331676A3 (en) Viral vaccines
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.